Scholarlink

Background <p>This study presents a retrospective analysis of palliative intra-arterial chemoperfusion (IAC) for patients with symptomatic breast cancer brain metastases (BCBM) aiming to investigate the safety and efficacy of the treatment.</p> Methods <p>Thirteen patients with BCBM were treated using a total of 64 IACs, averaging 4.9 per patient. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method. Response to IAC was evaluated according to RECIST 1.1.</p> Results <p>There were no treatment-related major complications. A total of three patients (3/11) developed progressive disease. Five (5/11) patients achieved stable disease, two (2/11) partial response, and one (1/11) complete response, resulting in a local tumor control rate of 73% (8/11). Two (2/13) patients could not be evaluated according to RECIST 1.1. The median OS time was 8.2 months (95% CI: 7.7–8.7), and the median PFS time was 7.9 months (95% CI: 0.0–16.3). The mean OS time was 14.5 months (95% CI: 3.4–25.6), and the mean PFS time was 10.6 months (95% CI: 2.6–18.6).</p> Conclusion <p>IAC can be applied as a safe method for palliative patients with BCBM. Further studies are necessary to definitively determine its efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intra-arterial chemoperfusion for breast cancer brain metastases: safety and efficacy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Hamzah Adwan,
  • Leon V. Stein,
  • Sven Becker,
  • Claus Rödel,
  • Thomas J. Vogl

摘要

Background

This study presents a retrospective analysis of palliative intra-arterial chemoperfusion (IAC) for patients with symptomatic breast cancer brain metastases (BCBM) aiming to investigate the safety and efficacy of the treatment.

Methods

Thirteen patients with BCBM were treated using a total of 64 IACs, averaging 4.9 per patient. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method. Response to IAC was evaluated according to RECIST 1.1.

Results

There were no treatment-related major complications. A total of three patients (3/11) developed progressive disease. Five (5/11) patients achieved stable disease, two (2/11) partial response, and one (1/11) complete response, resulting in a local tumor control rate of 73% (8/11). Two (2/13) patients could not be evaluated according to RECIST 1.1. The median OS time was 8.2 months (95% CI: 7.7–8.7), and the median PFS time was 7.9 months (95% CI: 0.0–16.3). The mean OS time was 14.5 months (95% CI: 3.4–25.6), and the mean PFS time was 10.6 months (95% CI: 2.6–18.6).

Conclusion

IAC can be applied as a safe method for palliative patients with BCBM. Further studies are necessary to definitively determine its efficacy.